GGrantIndex
← Search

Shared Resource: Proteomics & Metabolomics

$351,997P30FY2021CANIH

Fred Hutchinson Cancer Research Center, Seattle WA

Investigators

Linked publications, trials & patents

Trial NCT06995898Trial NCT06682039Trial NCT06484595Trial NCT06193070Trial NCT05947500Trial NCT05930496Trial NCT05183828Trial NCT04902144Trial NCT04751383Trial NCT04682301Trial NCT04667481Trial NCT04660331Trial NCT04539366Trial NCT04505553Trial NCT04502524Trial NCT04500548Trial NCT04496219Trial NCT04489719Trial NCT04472338Trial NCT04466475Trial NCT04447313Trial NCT04444232Trial NCT04442581Trial NCT04431479Trial NCT04410900Trial NCT04387227Trial NCT04384692Trial NCT04383743Trial NCT04375631Trial NCT04372927Trial NCT04370301Trial NCT04359784Trial NCT04336943Trial NCT04329065Trial NCT04282187Trial NCT04260776Trial NCT04257578Trial NCT04254133Trial NCT04231877Trial NCT04220229Trial NCT04211766Trial NCT04208724Trial NCT04205409Trial NCT04200482Trial NCT04198922Trial NCT04196010Trial NCT04195945Trial NCT04195633Trial NCT04194918Trial NCT04188912Trial NCT04175431Trial NCT04156828Trial NCT04155840Trial NCT04151940Trial NCT04120246Trial NCT04111497Trial NCT04083183Trial NCT04083170Trial NCT04081779Trial NCT04081298Trial NCT04062955Trial NCT04060849Trial NCT03999515Trial NCT03991884Trial NCT03986502Trial NCT03980769Trial NCT03970096Trial NCT03907527Trial NCT03891784Trial NCT03864419Trial NCT03807063Trial NCT03806192Trial NCT03781778Trial NCT03779867Trial NCT03779854Trial NCT03778021Trial NCT03776864Trial NCT03749460Trial NCT03747484Trial NCT03737955Trial NCT03723863Trial NCT03718338Trial NCT03672981Trial NCT03670966Trial NCT03670069Trial NCT03660930Trial NCT03649841Trial NCT03641287Trial NCT03606486Trial NCT03602898Trial NCT03600038Trial NCT03585231Trial NCT03574012Trial NCT03570476Trial NCT03531918Trial NCT03525106Trial NCT03523195Trial NCT03522584Trial NCT03518242Trial NCT03516812

Abstract

PROJECT SUMMARY: PROTEOMICS & METABOLOMICS SHARED RESOURCE (P&MSR) The Proteomics and Metabolomics Shared Resource (P&MSR) consists of the Fred Hutch (FH)-based Proteomics Facility and the University of Washington South Lake Union (UW-SLU) Metabolomics Facility. The P&MSR Proteomics Facility was formed in 2002 and has been under the direction of Dr. Phil Gafken since its inception. The P&MSR Metabolomics Facility was formed in 2013 and has been under the direction of Dr. Daniel Raftery. The mission of the P&MSR is (1) to provide high-quality, cost-effective, and reliable service in a timely manner for proteomics and metabolomics experiments; (2) to develop and implement new omics experiments, assays, and tools to uncover the molecular details influencing cancer biology; and (3) to support the development of translatable and clinical tests. The P&MSR operates and maintains chromatography, mass spectrometry, and nuclear magnetic resonance instruments and offers services such as experimental design and consultation, sample preparation and chromatography, protein or metabolite identification and quantification, protein modification characterization, targeted protein or metabolite quantification, metabolic flux analysis, and data analysis and informatics support. New technologies and services are continually being evaluated based on feedback from Consortium members. Over the next granting period, areas of interest that will be investigated include the analysis of major histocompatibility complex peptides to support cancer immunology and immunotherapy research. For metabolomics we will add to our over 20 current assays by expanding our capabilities to measure metabolic flux, provide the capability to investigate real-time metabolism studies using stable isotope tracers, and develop higher throughput global profiling assays to support research in cancer biology. With well-established operation policies, Consortium users have cost-effective, reliable, and immediate access to the P&MSR. The research supported by the P&MSR demonstrates that it is an important part of the critical Shared Resources infrastructure needed to support the Fred Hutch/University of Washington Cancer Consortium.

View original record on NIH RePORTER →